Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753139 | 0.93 | HRH4 (0.52) | CSNK1DMAPK14KDM4EALDH1A1HRH4 | |
| Tt-301 SCHEMBL529969 | 0.85 | CSNK1D (0.60) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| SCHEMBL1753099 | 0.85 | CSNK1D (0.60) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| Tt-301 SCHEMBL9998818 | 0.84 | CSNK1D (0.59) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| Tt-301 SCHEMBL300506 | 0.84 | CSNK1D (0.59) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| Tt-301 SCHEMBL529453 | 0.84 | CSNK1D (0.59) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| SCHEMBL18346578 | 0.84 | CSNK1D (0.60) | CSNK1DMAPK14MAPK11ROCK2ROCK1 | |
| SCHEMBL14679251 | 0.83 | LMNA (0.56) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| SCHEMBL1753053 | 0.80 | HRH4 (0.50) | CSNK1DMAPK14KDM4EALDH1A1LMNA | |
| SCHEMBL1752927 | 0.80 | HRH4 (0.51) | KDM4EALDH1A1HRH4HIF1AHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063894-B1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2063894-B1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| CN-101087766-A | Pyridazine compounds, compositions, and methods | UNIV NORTHWESTERN (US) | 2007-12-12 | — | — | CN | disclosed |
| WO-2007130383-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127375-A2 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127475-A2 | PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127474-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127474-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812408-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | Northwestern University (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050389-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | CSNK1D 1587/4885MAPK14 166/4885KDM4E 2926/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | CSNK1D 1547/4885MAPK14 126/4885KDM4E 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.